VIDEO: Data suggest bimekizumab will be ‘mainstay’ in psoriasis treatment

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the BE BRIGHT study.

Chovatiya, clinical associate professor at Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, discussed the long-term extension study that produced 4-year data into the use of bimekizumab (Bimzelx, UCB) for psoriasis treatment.

“(These data are) really saying that it’s going to be a mainstay in the game when we think about patients that are going to give rapid and complete clearance for our patients with moderate to severe psoriasis,” Chovatiya said.